Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts rate Omeros a "Moderate Buy" — six brokerages give a consensus rating (1 sell, 1 hold, 2 buy, 2 strong buy) with an average 12‑month price target of $40.33, well above the recent ~$11.49 share price.
• Omeros reported a surprising quarterly EPS of $3.14, beating estimates by $3.69, although analysts still forecast a negative full‑year EPS of about -3.09.
• Insider activity and institutional buying: CAO David J. Borges sold 30,000 shares at $12.31 (insiders own 12.9%), while large investors like Vanguard and UBS materially increased their stakes, leaving institutional ownership at 48.79%.

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $40.3333.

A number of equities research analysts recently commented on OMER shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Omeros in a research note on Thursday, January 22nd. Zacks Research raised shares of Omeros from a "hold" rating to a "strong-buy" rating in a research note on Thursday, April 2nd. D. Boral Capital reissued a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th. Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research note on Saturday, April 4th. Finally, HC Wainwright increased their price objective on shares of Omeros from $20.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, January 8th.

Insider Buying and Selling

In related news, CAO David J. Borges sold 30,000 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 12.90% of the company's stock.

Institutional Investors Weigh In On Omeros

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company's stock valued at $68,929,000 after acquiring an additional 666,357 shares during the last quarter. UBS Group AG boosted its stake in shares of Omeros by 213.5% during the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock worth $38,180,000 after purchasing an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Omeros by 6.3% during the 4th quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company's stock worth $28,026,000 after purchasing an additional 95,979 shares during the last quarter. State Street Corp boosted its stake in shares of Omeros by 26.9% during the 4th quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company's stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Omeros by 39.3% during the 3rd quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company's stock worth $3,827,000 after purchasing an additional 263,095 shares during the last quarter. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Stock Down 3.5%

Shares of OMER opened at $11.49 on Friday. The company has a 50-day simple moving average of $11.30 and a 200-day simple moving average of $10.12. The company has a market capitalization of $827.28 million, a PE ratio of -22.98 and a beta of 2.53. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.55) by $3.69. On average, research analysts anticipate that Omeros will post -3.09 EPS for the current year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.